Insmed (NASDAQ:INSM) Price Target Cut to $175.00 by Analysts at JPMorgan Chase & Co.

JPMorgan Chase & Co. has lowered its price target for Insmed (NASDAQ:INSM) to $175.00 from $179.00, while maintaining an "overweight" rating. This adjustment comes despite Insmed exceeding quarterly earnings expectations, reporting a loss of $0.06 per share against a forecasted $0.67 loss and a significant revenue increase of 296.1% year-over-year to $425.49 million. The biopharmaceutical company still holds a consensus "Buy" rating and an average price target of $205.52 from other analysts.